Thomas Högberg

发表

QSAR on Substituted Salicylamides Using with Implementation of 3D MEP Descriptors

Ulf Norinder, Thomas Högberg, 1991 .

Widening bottlenecks in drug discovery: glimpses from Drug Discovery Technology Europe 2005.

Thomas Högberg, 2005, Drug discovery today.

Dopamine D2 receptors in the rat, monkey and the post-mortem human hippocampus. An autoradiographic study using the novel D2-selective ligand 125I-NCQ 298

Christer Halldin, V. Chan‐Palay, H. Ericson, 1991, Neuroscience Letters.

Melanin concentrating hormone receptor 1 (MCHR1) antagonists-Still a viable approach for obesity treatment?

Thomas M Frimurer, T. Frimurer, T. Högberg, 2012, Bioorganic & medicinal chemistry letters.

4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists.

Trond Ulven, T. Högberg, T. Ulven, 2004, Bioorganic & medicinal chemistry letters.

Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier.

Martin Cooper, Anthony Murray, T. Högberg, 2010, Bioorganic & medicinal chemistry letters.

Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits.

Evi Kostenis, Thomas M Frimurer, Trond Ulven, 2006, Journal of medicinal chemistry.

Synthesis of [methoxy-3H]- and [methoxy-11C]- labelled raclopride. Specific dopamine-D2 receptor ligands

T. Högberg, E. Ehrin, Thomas Högberg, 1987 .

6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode.

Thomas M Frimurer, Trond Ulven, T. Frimurer, 2005, Journal of medicinal chemistry.

A physicogenetic method to assign ligand-binding relationships between 7TM receptors.

Evi Kostenis, Thomas M Frimurer, Trond Ulven, 2005, Bioorganic & medicinal chemistry letters.